Literature DB >> 26511970

Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.

Liao Sun1, Xiaohong Wei2, Xueting Liu2, Danli Zhou2, Fang Hu2, Yingjuan Zeng2, Ying Sun2, Shunkui Luo2, Yu Zhang2, Xian Ping Yi3.   

Abstract

The objective of the present study is to determine the role of prostaglandin E2 (PGE2) and downstream EP receptors in the development of human papillary thyroid carcinoma (PTC). A total of 90 thyroid specimens excised from patients undergoing total or subtotal thyroidectomy in the Department of General Surgery, the Fifth Affiliated Hospital of Sun Yat-sen University, China, from August 2013 to September 2014, were analyzed. The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunohistochemical analyses were employed to examine the messenger RNA (mRNA) and protein expression, respectively. The expressions and significances of cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1), PGE2, and EP receptors in PTC and nodular goiter were investigated. The COX-2 mRNA and protein expression level significantly increased in the PTC tissues than in the paired noncarcinoma tissues adjacent to the PTC or nodular goiter tissues. The mPGES-1 protein expression was also significantly upregulated in the PTC tissues. All the four subtypes of EP receptors (EP1-4) could express in the thyroid tissues, while only the EP4 mRNA and protein levels significantly increased in the PTC tissues. The local production of PGE2 had a higher-level expression in the PTC tissues than in the noncarcinoma thyroid tissues adjacent to the PTC lesion and the benign nodular goiter tissues. The induction of PGE2 biosynthesis as well as the overexpression of EP4 in PTC suggested that this pathway might play an important role in the carcinogenesis and progression of PTC. These observations raise the possibility that pharmacological inhibition of mPGES-1 and/or EP4 may hold therapeutic promise in this common cancer.

Entities:  

Keywords:  Cyclooxygenase-2; EP4 receptor; Microsomal prostaglandin E synthase-1; Papillary thyroid carcinoma; Prostaglandin E2

Mesh:

Substances:

Year:  2015        PMID: 26511970     DOI: 10.1007/s13277-015-4316-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  42 in total

1.  Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.

Authors:  Xiping Xin; Mousumi Majumder; Gannareddy V Girish; Vik Mohindra; Takayuki Maruyama; Peeyush K Lala
Journal:  Lab Invest       Date:  2012-05-28       Impact factor: 5.662

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway.

Authors:  Robert J George; Mark A Sturmoski; Shrikant Anant; Courtney W Houchen
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-01-03       Impact factor: 3.072

4.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

Review 5.  Prostaglandin E receptors.

Authors:  Yukihiko Sugimoto; Shuh Narumiya
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

Review 7.  The prostanoid EP4 receptor and its signaling pathway.

Authors:  Utako Yokoyama; Kousaku Iwatsubo; Masanari Umemura; Takayuki Fujita; Yoshihiro Ishikawa
Journal:  Pharmacol Rev       Date:  2013-06-17       Impact factor: 25.468

8.  Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence.

Authors:  Simon D Chell; Ian R Witherden; Richard R Dobson; Morganaden Moorghen; Andrew A Herman; David Qualtrough; Ann C Williams; Christos Paraskeva
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

9.  TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.

Authors:  Baohan T Vo; Derrick Morton; Shravan Komaragiri; Ana C Millena; Chelesie Leath; Shafiq A Khan
Journal:  Endocrinology       Date:  2013-03-20       Impact factor: 4.736

10.  Assessment of cyclooxygenase-1 and 2 gene expression levels in chronic autoimmune thyroiditis, papillary thyroid carcinoma and nontoxic nodular goitre.

Authors:  Kinga Krawczyk-Rusiecka; Katarzyna Wojciechowska-Durczynska; Anna Cyniak-Magierska; Arkadiusz Zygmunt; Andrzej Lewinski
Journal:  Thyroid Res       Date:  2014-12-17
View more
  1 in total

1.  The Synergistic Effects of Celecoxib and Sodium Valproate on Apoptosis and Invasiveness Behavior of Papillary Thyroid Cancer Cell Line In-vitro.

Authors:  Maryam Fanian; Maedeh Bahmani; Mojdeh Mozafari; Samaneh Naderi; Marzieh Alizadeh Zareie; Mohammad Ali Okhovat; Jamileh Saberzadeh; Ali Dehshahri; Mohammad Ali Takhshid
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.